Corneal Endothelial Dystrophy Market: By Treatment (Phototherapeutic Keratectomy, Amniotic Membrane Transplants, Anterior Stromal Puncture, Conjunctival Flaps), By Disease Type (Congenital Hereditary Endothelial Dystrophy 1, Congenital Hereditary Endothelial Dystrophy 2, Posterior Polymorphous Corneal Dystrophy, and Fuchs Endothelial Corneal Dystrophy), By Diagnosis (Cornea Examination and Grading, Corneal Tomography, Corneal Pachymetry, Corneal Cell Count, and Others), By End Users (Hospitals, Clinics, Others) and Geography

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Corneal Endothelial Dystrophy Market was valued at USD 168 billion in 2022 and is poised to grow at a CAGR of 7.5% over 2023-2029. Corneal endothelial dystrophy is a group of rare hereditary disorders characterized by bilateral abnormal deposition of substances in the cornea. Based on the diagnosis type, the cornea examination and grading segment is anticipated to dominate the corneal endothelial dystrophy market share over the forecast period. According to the American Academy of Ophthalmology, congenital corneal opacities have a prevalence of 6:1,00,000 in newborns and 3:1,00,000 excluding congenital glaucoma patients. With an increasingly aging population, awareness of the disorder is also increasing, driving the corneal endothelial dystrophy market growth. However, the side effects associated with the treatment procedures might hinder the market growth. Initiatives by the government and increasing reimbursement policies are opportunities for the growth of the market.

Corneal Endothelial Dystrophy Market Key Developments:
  • In May 2023, Trefoil Therapeutics released updated efficacy data from the phase-II STORM trial in Fuchs endothelial dystrophy for TTHX-1114.

Corneal Endothelial Dystrophy Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

North America
Corneal Endothelial Dystrophy Market Dynamics

There has been an increase in technologies involved in the diagnosis and treatment of the disease with an increased clinical trial in the eye disease segment owing to the growing healthcare expenditures. For Instance, Rhopressa (Netarsudil ophthalmic solution), developed by Aerie Pharmaceuticals is used in the treatment of Fuchs endothelial corneal dystrophy. Thus, the increased awareness, research, and development for rare disorders will lead to the growth of the market within the forecast period. Whereas the high cost of treatment could pose as a restraining factor for the market growth.

Key Features of the Reports

  • The corneal endothelial dystrophy market report provides granular level information about the market size, regional market share, historic market (2018-2022) and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Corneal Endothelial Dystrophy Market Segmentation

By Treatment
  • Phototherapeutic Keratectomy
  • Amniotic Membrane Transplants
  • Anterior Stromal Puncture
  • Conjunctival Flaps
By Disease Type
  • Congenital Hereditary Endothelial Dystrophy 1
  • Congenital Hereditary Endothelial Dystrophy 2
  • Posterior Polymorphous Corneal Dystrophy
  • Fuchs Endothelial Corneal Dystrophy
By Diagnosis
  • Cornea Examination and Grading
  • Corneal Tomography
  • Corneal Pachymetry
  • Corneal Cell Count
  • Others
By End User
  • Hospitals
  • Clinics
  • Others

Frequently Asked Questions

The corneal endothelial dystrophy market was valued at USD 168 billion in 2022 and is expected to grow at a 7.5% CAGR over the forecast period 2023 – 2029.

Initiatives by the government and increasing reimbursement policies are key opportunities for the corneal endothelial dystrophy market.

An increasing aging population and a rise in awareness of the disorder are the growth drivers in the corneal endothelial dystrophy market.

Kowa Company, Ltd., Trefoil Therapeutics, Alcon, Price Vision Group, ProQR Therapeutics, Emmecell, Pfizer Inc., GlaxoSmithKline plc., Bausch Health Companies Inc., Bayer AG, Allergan, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., and Novartis AG are a few companies operating in the Corneal Endothelial Dystrophy market.

  • Kowa Company, Ltd.
  • Trefoil Therapeutics
  • Alcon
  • Price Vision Group
  • ProQR Therapeutics
  • Emmecell
  • Pfizer Inc.
  • GlaxoSmithKline plc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Allergan
  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Novartis AG